Hester Biosciences Ltd.

NSE: HESTERBIO BSE: 524669 SECTOR: Pharmaceuticals & Drugs  23k   124   12

1766.20
+8.70 (0.50%)
NSE: Today, 03:41 PM

Price Summary

Today's High

₹ 1786.2

Today's Low

₹ 1761

52 Week High

₹ 2949.6

52 Week Low

₹ 1719.05

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyExcellent
The company knows very well the utilization of its assets.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1502.48 Cr.

Enterprise Value

1622.41 Cr.

No. of Shares

0.85 Cr.

P/E

48.69

P/B

5.46

Face Value

₹ 10

Div. Yield

0.56 %

Book Value (TTM)

₹  323.57

CASH

1.98 Cr.

DEBT

121.91 Cr.

Promoter Holding

53.73 %

EPS (TTM)

₹  36.27

Sales Growth

5.22%

ROE

15.62 %

ROCE

17.31%

Profit Growth

-0.96 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Hester Biosciences Ltd.

Xester Toxcinil Inomilk Reproplus CurX Fensafe Allgone Amastic

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year5.22%
3 Year8.61%
5 Year12.21%

Profit Growth

1 Year-0.96%
3 Year-3.41%
5 Year9.64%

ROE%

1 Year15.62%
3 Year16.68%
5 Year19.96%

ROCE %

1 Year17.31%
3 Year20.11%
5 Year23.55%

Debt/Equity

0.4542

Price to Cash Flow

94.47

Interest Cover Ratio

22.5786061588331

CFO/PAT (5 Yr. Avg.)

0.817647588224953

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2022 53.73 0
Sep 2022 53.73 0
Jun 2022 53.73 0
Mar 2022 53.73 0
Dec 2021 53.73 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has been maintaining healthy ROCE of 20.1117952762293% over the past 3 years.
  • Company has a healthy Interest coverage ratio of 22.5786061588331.
  • The Company has been maintaining an effective average operating margins of 33.724998508112% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 2.22446116225931.
  • The company has a high promoter holding of 53.73%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 8.77853722819097.

 Limitations

  • The company has shown a poor profit growth of -3.4102120780293% for the Past 3 years.
  • The company has shown a poor revenue growth of 8.61503201206548% for the Past 3 years.
  • Company has contingent liabilities of 106.445 Cr.
  • The company is trading at a high PE of 48.69.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022
Net Sales 56.59 54 50.25 50.53 72
Total Expenditure 39.46 38.77 40.2 41.33 56.22
Operating Profit 17.14 15.23 10.05 9.2 15.78
Other Income 1.32 1.22 1.08 1.23 2.18
Interest 0.35 0.37 1.38 1.27 1.74
Depreciation 2.32 2.33 2.55 2.39 2.34
Exceptional Items 0 0 0 0 0
Profit Before Tax 15.78 13.75 7.2 6.77 13.88
Tax 4.01 3.2 2.26 1.77 3.53
Profit After Tax 11.77 10.56 4.95 5.01 10.35
Adjusted EPS (Rs) 13.84 12.41 5.82 5.88 12.16

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Net Sales 134.79 171.19 169.43 208.48 219.35
Total Expenditure 85.19 103.42 116.7 136.48 160.74
Operating Profit 49.6 67.76 52.72 71.99 58.61
Other Income 1.88 3.1 2.93 1.65 6.61
Interest 2.32 3.54 5.03 3.95 2.47
Depreciation 5.45 7.57 9.39 9.63 9.5
Exceptional Items 0 0 0 -5.28 0
Profit Before Tax 43.71 59.75 41.23 54.78 53.26
Tax 13.15 15.9 10.01 14.88 13.74
Net Profit 30.56 43.85 31.22 39.9 39.52
Adjusted EPS (Rs.) 35.92 51.55 36.7 46.9 46.45

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Equity and Liabilities
Share Capital 8.51 8.51 8.51 8.51 8.51
Total Reserves 137.57 170.93 194.57 229.07 259.93
Borrowings 14.61 11.37 7.45 2.68 73.25
Other N/C liabilities 7.37 10.14 8.44 7.11 7.92
Current liabilities 42.43 39.3 58.22 34.65 74.84
Total Liabilities 210.49 240.24 277.19 282.02 424.44
Assets
Net Block 66.74 100.81 96.76 86.69 84.31
Capital WIP 30.47 0.42 0.87 3.29 80.22
Intangible WIP 0 0 0 0.43 1.69
Investments 14.48 28.22 40.67 43.89 64.69
Loans & Advances 9.59 9.81 11.83 5.32 24.2
Other N/C Assets 0.08 1.58 3.87 2.8 2.86
Current Assets 89.13 99.4 123.18 139.61 166.47
Total Assets 210.49 240.24 277.19 282.02 424.44
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Profit from operations 43.71 59.75 41.23 54.78 53.26
Adjustment 7.34 8.5 12.25 19.61 11.7
Changes in Assets & Liabilities -9.37 -16.47 -16.31 -19.8 -32.61
Tax Paid -9.39 -15.58 -11.35 -13.49 -16.44
Operating Cash Flow 32.28 36.19 25.82 41.1 15.91
Investing Cash Flow -26.32 -24.7 -21.33 -3.72 -110.58
Financing Cash Flow -6.24 -20.29 -1.39 -41.33 94.96
Net Cash Flow -0.28 -8.8 3.1 -3.95 0.28

Corporate Actions

Investors Details

PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Promoters 53.73 53.73 53.73 53.73 53.73
rajiv d gandhi - 10.41 10.41 10.41 10.41
rajiv dinesh gandhi 10.47 - - - -
sanjiv dinesh gand... 8.20 8.14 8.14 8.14 8.14
nina r gandhi - 8.19 8.19 8.19 8.19
nina rajiv gandhi 8.19 - - - -
ravin gandhi 4.74 4.74 4.74 4.74 4.74
bela gandhi 4.71 4.71 4.71 4.71 4.71
bhupendra vithalda... 4.69 4.69 4.69 4.69 4.69
bhupendra v gandhi... - - - 3.66 -
bhupendra vithalda... 3.55 3.66 3.66 - 3.66
biolink healthcare... 2.93 2.93 2.93 2.93 2.93
madhuri kapadia - - 2.37 2.41 2.37
anup chandravadan ... 2.68 2.68 0.32 0.32 0.32
shaila bhupendra g... 2.23 2.23 2.23 2.23 2.23
hester coatings llp 0.75 0.75 0.75 0.75 0.75
hester diagnostics... 0.28 0.28 0.28 0.28 0.28
hetal sanjiv gandhi 0.23 0.23 0.23 0.23 0.23
yash rajiv gandhi 0.09 0.09 0.09 0.04 0.09
PARTICULARS Dec 2021% Mar 2022% Jun 2022% Sep 2022% Dec 2022%
Investors 46.27 46.27 46.27 46.27 46.27
kuntal hasmukhlal ... 3.05 2.96 2.85 2.63 2.85
manish jain 2.55 2.56 2.41 2.38 2.41
darshna dinesh kap... 1.81 1.63 1.63 1.63 1.63
vinay shah 1.28 1.28 1.28 1.28 1.28
investor education... 0.93 - - - -
iepf - 0.78 0.79 0.79 0.79
llp 0.36 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Hester Biosciences informs about loss of share certificate9 Jan 2023, 12:10PM Hester Biosciences acquires technology from ICAR-NIHSAD to develop H9N2 strain vaccine for poultry28 Dec 2022, 2:28PM Hester Biosciences informs about loss of share certificate19 Dec 2022, 11:36AM Hester Biosciences informs about disclosure of related party transactions16 Nov 2022, 4:31PM Hester Biosciences informs about newspaper publication 7 Nov 2022, 11:19AM Hester Biosciences informs about transcript of earnings conference call7 Nov 2022, 11:16AM Hester Biosciences - Quaterly Results4 Nov 2022, 12:27PM Hester Biosciences - Quaterly Results4 Nov 2022, 12:27PM Hester Biosciences - Quaterly Results4 Nov 2022, 12:27PM Hester Biosciences informs about loss of share certificate 22 Aug 2022, 12:59PM Hester Biosciences informs about newspaper publication12 Aug 2022, 10:03AM Hester Biosciences - Quaterly Results10 Aug 2022, 12:08PM Hester Biosciences - Quaterly Results10 Aug 2022, 12:08PM Hester Biosciences - Quaterly Results10 Aug 2022, 12:08PM Hester Biosciences informs about conference call8 Aug 2022, 12:17PM Hester Biosciences informs about newspaper publication30 Jul 2022, 11:01AM Hester Biosciences informs about book closure for dividend & AGM 29 Jul 2022, 4:45PM Hester Biosciences informs about press release20 Jul 2022, 3:10PM Hester Biosciences - Quaterly Results20 May 2022, 12:43PM Hester Biosciences - Quaterly Results20 May 2022, 12:43PM Hester Biosciences - Quaterly Results20 May 2022, 12:43PM Hester Biosciences gets Rs 60 crore grant from BIRAC to support COVID-19 vaccine manufacturing8 Apr 2022, 11:16AM Hester Biosciences informs about compliance certificate6 Apr 2022, 12:38PM Hester Biosciences to venture into pet care industry22 Mar 2022, 2:36PM Hester Biosciences informs about outcome of board meeting31 Jan 2022, 4:44PM Hester Biosciences informs about outcome of board meeting31 Jan 2022, 12:54PM Hester Biosciences - Quaterly Results31 Jan 2022, 11:57AM Hester Biosciences - Quaterly Results31 Jan 2022, 11:57AM Hester Biosciences informs about earnings conference call25 Jan 2022, 9:51AM Hester Biosciences informs about loss of share certificate 22 Nov 2021, 10:45AM Hester Biosciences enters into agreement to acquire 50% stake in Thrishool Exim9 Nov 2021, 5:20PM Hester Biosciences informs about acquisition9 Nov 2021, 5:18PM Hester Biosciences informs about newspaper clippings 29 Oct 2021, 10:24AM Hester Biosciences informs about outcome of board meeting28 Oct 2021, 4:04PM Hester Biosciences informs about press release28 Oct 2021, 1:09PM Hester Biosciences informs about earnings conference call22 Oct 2021, 10:39AM Hester Biosciences informs about closure of trading window30 Sep 2021, 1:19PM Hester Biosciences informs about outcome of board meeting12 Aug 2021, 12:37PM Hester Biosciences informs about newspaper clipping24 Jul 2021, 12:06PM Hester Biosciences informs about certificate7 Jul 2021, 12:11PM Hester Biosciences submits transcript of earnings conference call16 Jun 2021, 12:11PM Hester Biosciences informs about loss of share certificate16 Jun 2021, 12:09PM Hester Biosciences informs about newspaper clippings 10 Jun 2021, 12:20PM Hester Biosciences informs about earnings conference call4 Jun 2021, 12:08PM Hester Biosciences informs about outcome of board meeting29 May 2021, 2:09PM Hester Biosciences informs about board meeting27 May 2021, 2:20PM Hester Biosciences informs about board meeting27 May 2021, 2:15PM Hester Biosciences informs about clarification 17 May 2021, 3:30PM Hester Biosciences ties up with Gujarat government to explore production of COVID-19 vaccine17 May 2021, 11:43AM Hester launches range of Herbal Veterinary Products24 Apr 2021, 11:21AM

Hester Biosciences Stock Price Analysis and Quick Research Report. Is Hester Biosciences an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Hester Biosciences and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Its cash from the operating activity was Rs 15.905 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Hester Biosciences has a Debt to Equity ratio of 0.4542 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Hester Biosciences , the EPS growth was -0.962397422804597 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Hester Biosciences has OPM of 26.7206440818597 % which is a good sign for profitability.
     
  • ROE: Hester Biosciences have a average ROE of 15.6189045779275 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
Brief about Hester Biosciences

X